Lack of clinical efficacy of imatinib in metastatic melanoma - Wikidata - awgldk - TriplyDB

Lack of clinical efficacy of imatinib in metastatic melanoma

Lack of clinical efficacy of imatinib in metastatic melanoma

http://www.wikidata.org/entity/Q36616712

about

Melanoma: from melanocyte to genetic alterations and clinical options Analysis of the genome to personalize therapy for melanoma Melanoma: new insights and new therapies Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.KGF Promotes Paracrine Activation of the SCF/c-KIT Axis from Human Keratinocytes to Melanoma Cells.Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma Understanding the biology of melanoma and therapeutic implications Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type Driver mutations in melanoma: lessons learned from bench-to-bedside studies New horizons in melanoma treatment: targeting molecular pathways.Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry NUAK2: an emerging acral melanoma oncogene Comparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa.Targeted agents for the treatment of metastatic melanoma.Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.Targeting drivers of melanoma with synthetic small molecules and phytochemicals.Drug targets and predictive biomarkers in the management of metastatic melanoma.Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies.New approaches in metastatic melanoma: biological and molecular targeted therapies.Phase II trial of imatinib mesylate in patients with metastatic melanoma.Molecular targets in melanoma: time for 'ethnic personalization'Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas Recent discoveries in the genetics of melanoma and their therapeutic implications.Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts.Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.Growth factors and oncogenes as targets in melanoma: lost in translation?Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer.The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.Melanoma biology and the promise of zebrafish.Molecular-targeted therapy in malignant melanoma.Novel therapeutics for melanoma.SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.KIT as a therapeutic target in metastatic melanoma.BRAF and beyond: Tailoring strategies for the individual melanoma patient Mutation-driven drug development in melanoma.

P2860

Q21284811-F692AA80-15E8-4F9A-8AE7-C3AC26DC3A7C Q24601008-BF8427CC-10E5-4070-9574-77B263E4814B Q26853127-4E0D584F-2FDF-444B-8532-CDB131DEE311 Q27851482-DFFAB9FD-12FF-4FD1-B51C-261E4701F62C Q27852360-79E5CEB1-350F-480A-A0C0-E875E4431F28 Q33711241-42B56E65-2C59-4EC1-9078-8BB4E170650E Q33760584-6847C54F-44B3-420E-AAAE-C48E549B5065 Q33790743-88B01359-B0E5-456C-987A-C5A04383E28E Q33978378-9D3F7202-9ECD-422F-82E1-81E488B2DB6E Q33995919-D6E4F8F4-0368-4E1C-996C-625F22E39311 Q34639532-13082323-E7A2-4B1B-B7B6-CB72D2B84E44 Q34986188-CD7A60E2-ED46-4B14-B15B-F56590BBAF21 Q35169273-E017A614-BC56-4836-8D78-1BF65989C811 Q35640334-38F73479-1A1A-4397-BC4C-DE31F20A4A6D Q35765288-FFAFBA3F-3088-4E41-9047-3CDD8AC35E99 Q35822194-F07F87C8-E9C7-4855-9F65-BF1A02C4DBCF Q35915719-427F176F-97C4-447B-87DA-2FC5740807CD Q36141097-1FA1FF10-B77C-4DB1-89FC-39139245C3FA Q36441552-E0FAA73B-8E02-4214-B63C-54FE5F4914E9 Q36707344-227D7F4F-90F3-4AF2-ACF9-F4B7C23CBD90 Q36817127-A58B6519-B6C6-40DB-A37C-DF6B0580F361 Q36859215-504B7BA4-178E-44C5-8AA2-DDAAD78929EF Q36927065-8631D8E2-6D3E-457E-9C2D-9C98DE847F27 Q36940730-96307B22-83D0-4ACF-9841-D3F2F3E900A5 Q37023924-3B3650BB-62A6-4C2A-BBDA-D6F919D3FC56 Q37024839-5043C74C-0185-448B-8AE2-9D22E3BDCF25 Q37036301-79DF30FA-2AEC-4DF2-B4CB-8C6E239167FA Q37042015-66C1128D-3F36-4346-BF7B-D659EA408A41 Q37045217-1A99BF9B-24C7-4F8C-8140-36C7C0CCB02E Q37132792-F399CF72-415D-4018-B101-C9C7DB0C092F Q37290440-962F0E67-DCA2-4E44-B362-DBB7D84A60C0 Q37365611-82DC6324-091E-494E-9873-92530561C577 Q37483949-3711CCD9-F759-4128-BF2E-DD6C8B0B09AA Q37508041-F7E8E942-1AC8-466F-A08D-9B44B4BB71F7 Q37509699-B6A10E02-B7D1-4287-AF00-4D9C499341CD Q37605787-28C65062-F2D1-4FD3-BBE5-5D0454FD5E88 Q37628695-1B93A2A0-81A6-4CDF-AC34-84145B25FE83 Q37701887-69D07302-1C45-47E2-9FD1-E756CC5B0EA5 Q37702515-07DA5612-DB55-4D95-BA77-DD3DBC362A93 Q37733450-8A02A679-3DFF-4438-949A-2B660A97660E

P2860

Lack of clinical efficacy of imatinib in metastatic melanoma

http://www.wikidata.org/entity/Q36616712

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Lack of clinical efficacy of imatinib in metastatic melanoma

@ast

Lack of clinical efficacy of imatinib in metastatic melanoma

@en

type

label

Lack of clinical efficacy of imatinib in metastatic melanoma

@ast

Lack of clinical efficacy of imatinib in metastatic melanoma

@en

prefLabel

Lack of clinical efficacy of imatinib in metastatic melanoma

@ast

Lack of clinical efficacy of imatinib in metastatic melanoma

@en

P1433

Q36616712-9952E296-3D48-4011-9ABF-513F62FD90B5

P1476

Q36616712-C3AC215C-607C-4989-B4DC-8D43625B4949

P2093

Q36616712-1B1B3E18-C4D2-4A4E-8A37-4BE7313C3228

Q36616712-51D90B5A-EF9C-4C2E-8FF8-D493E9B906CF

Q36616712-5269428E-806F-4F9C-9363-85AAB624FC3C

Q36616712-7EA19D18-DBDA-4D32-8B44-74D0E00C01CF

Q36616712-B72DCCEC-8CF5-41E2-9455-CFC13A18836D

Q36616712-C42B84CC-ED49-4A31-9DFB-BA8EDE68A595

Q36616712-D53B7EF8-9B39-4FD0-A55F-64D6E140A855

Q36616712-E7A75D1E-6BB2-482D-95C1-75F7F0EA0EC7

Q36616712-FEAEF17D-3F2D-4ED7-AB6C-AB33A02719ED

P2860

Q36616712-025AA068-5AAF-4966-92D2-608603162D17

Q36616712-0C954006-4E83-4EC8-9EE9-EB909EB5DD29

Q36616712-0F9B2C64-50D3-4CCE-8B03-CE91347CFE3A

Q36616712-126D566B-FAD5-4181-A735-9D7F5EDA6200

Q36616712-19E4BA8C-BB1A-4F1C-9B90-0872F4292203

Q36616712-25DDA316-EAB7-498A-B9E7-F0F5AE1413E3

Q36616712-308E9F39-EEE1-4F74-97B7-5D9927AB345E

Q36616712-31B215FB-1D0D-4DB6-953A-A624043AA8A1

Q36616712-31E0247A-8D74-4E23-9C9E-A75FAA34145E

Q36616712-3668F3F8-5C8E-45FE-AF10-89876F5D1056

P2888

Q36616712-A7C025F2-EB78-441E-9F85-25E1C91CFD73

P304

Q36616712-DB7EE646-9AF0-4618-BAFA-41BEB0BFC195

P31

Q36616712-2C4DBCE3-10F6-4752-A052-E8C0697EBC1D

P356

Q36616712-5E672805-BC97-47DF-98B4-73786C002AFB

P407

Q36616712-526E5D47-05DF-4DEC-B910-173DD38EC11D

P433

Q36616712-AF4A1C97-67C0-413E-AA29-430A42A87DB1

P478

Q36616712-174FBEE6-846B-4BBD-AC09-528872E2E59A

P50

Q36616712-8ADCD795-0EAB-4F0C-9570-CD111DA0F73F

Q36616712-94FC7F80-0D46-4379-8D2D-D922EA8C40FA

P577

Q36616712-E1FE26E0-9794-4396-85C5-25663733109D

P5875

Q36616712-76194192-34A2-4ED4-8EAC-C6FC4388B17A

P698

Q36616712-E582B3FE-B551-4056-9C58-F3467135A3C3

P932

Q36616712-2D2D8649-E010-41D9-AA87-D12C580E1143

P356

P1433

British Journal of Cancer

P1476

Lack of clinical efficacy of imatinib in metastatic melanoma

@en

P2093

A Sucker

http://www.w3.org/2001/XMLSchema#string

A Zimpfer

http://www.w3.org/2001/XMLSchema#string

D Schadendorf

http://www.w3.org/2001/XMLSchema#string

J C Becker

http://www.w3.org/2001/XMLSchema#string

P Keikavoussi

http://www.w3.org/2001/XMLSchema#string

P Paschka

http://www.w3.org/2001/XMLSchema#string

R Hildenbrand

http://www.w3.org/2001/XMLSchema#string

S Ugurel

http://www.w3.org/2001/XMLSchema#string

W Rittgen

http://www.w3.org/2001/XMLSchema#string

P2860

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

P2888

P304

1398-1405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602529

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Hochhaus

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7891891

http://www.w3.org/2001/XMLSchema#string

P698

15846297

http://www.w3.org/2001/XMLSchema#string

P932

2362005

http://www.w3.org/2001/XMLSchema#string